首页 | 本学科首页   官方微博 | 高级检索  
     

二甲双胍对新型冠状病毒肺炎合并冠心病糖尿病患者心肌损伤的保护作用
引用本文:黄振华,刘青云,刘亚坤,唐飞飞,刘喆隆,高思海. 二甲双胍对新型冠状病毒肺炎合并冠心病糖尿病患者心肌损伤的保护作用[J]. 中国胸心血管外科临床杂志, 2021, 0(4): 396-403
作者姓名:黄振华  刘青云  刘亚坤  唐飞飞  刘喆隆  高思海
作者单位:华中科技大学同济医学院附属同济医院心脏大血管外科;华中科技大学同济医学院附属同济医院内分泌科
基金项目:国家自然科学基金(81570090)。
摘    要:目的 探讨冠状动脉粥样硬化性心脏病(冠心病)合并糖尿病人群在感染新型冠状病毒肺炎(COVID-19)后,服用的二甲双胍是否对心肌损伤有保护作用.方法 选取同济医院2020年1月18日至4月25日入院治疗的COVID-19合并冠心病及糖尿病的患者.根据其是否服用二甲双胍分为二甲双胍组和无二甲双胍(对照组).回顾性分析两组...

关 键 词:新型冠状病毒肺炎  二甲双胍  心脏损伤  糖尿病  冠状动脉粥样硬化性心脏病

Protective effects of metformin on myocardial injury in patients with COVID-19 combined with coronary heart diseases and diabetes
HUANG Zhenhua,LIU Qingyun,LIU Yakun,TANG Feifei,LIU Zhelong,GAO Sihai. Protective effects of metformin on myocardial injury in patients with COVID-19 combined with coronary heart diseases and diabetes[J]. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2021, 0(4): 396-403
Authors:HUANG Zhenhua  LIU Qingyun  LIU Yakun  TANG Feifei  LIU Zhelong  GAO Sihai
Affiliation:(Department of Cardiothoracic and Vascular Surgery,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,430030,P.R.China;Department of Endocrinology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,430030,P.R.China)
Abstract:Objective To investigate whether metformin has protective effect on myocardial injury in patients with coronavirus disease 2019(COVID-19)combined with coronary heart diseases and diabetes.Methods COVID-19 patients with coronary heart disease and diabetes who were admitted to Tongji Hospital from January 18 to April 25 in 2020 were enrolled.They were divided into a metformin group and a none-metformin group according to whether the metformin was used.The demographic characteristics,clinical symptoms,laboratory parameters,treatment and clinical outcomes of the two groups were analyzed retrospectively.Results There were 29 patients in the metformin group,3 patients(12.0%,3/25)suffered myocardial injury and 1(3.4%)died of acute respiratory failure complicated by septic shock;67 patients were in the non-metformin group and 24(37.5%,24/64)had myocardial injury but 15 died in hospital among whom 1 died of septic shock complicated by disseminated intravascular coagulation,1 acute respiratory failure complicated by possible cerebral hemorrhage,2 acute respiratory failure,1 fulminant myocarditis,3 acute myocardial infarction and 7 cardiac arrest.The incidence of myocardial injury(12.0%vs.37.5%,P=0.019),hospital mortality(3.4%vs.22.4%,P=0.034)and mortality of cardiovascular events(0.0%vs.16.4%,P=0.049)in the metformin group were significantly lower than those in the non-metformin group.Multivariate analysis showed that the use of insulins(OR=11.235,P=0.003)was an influencing factor for in-hospital mortality of patients.The use of metformin(OR=0.154,P=0.013)was positively correlated with the myocardial injury.Conclusion When patients with coronary heart disease and diabetes are infected with COVID-19,metformin can effectively reduce myocardial damage and has a certain effect on reducing hospital mortality.Combined with clinical considerations,it is worthy of popularization.
Keywords:Coronavirus disease 2019(COVID-19)  metformin  heart injuries  diabetes  coronary heart diseases
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号